FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. What is presented is a vector based on herpes simplex virus (HSV), which does not express toxic HSV genes ICP0, ICP4, ICP22, ICP27 and, if necessary, ICP47 in non-complementary cells. Vector contains mutant HSV genome containing genetic rearrangements in comparison to HSV of wild type, namely inactivating deletion of gene coding ICP0, inactivating deletion of gene coding ICP4, gene coding ICP22, which is under control of early promoter, inactivating deletion of gene coding ICP27, and, if necessary, inactivating deletion of gene coding ICP47. Vector is able to express the transgene for at least 28 days in non-complementary cells.
EFFECT: invention enables to express a transgene in any tissue or cell in vitro or in vivo without damage to the cell or tissue.
34 cl, 32 dwg, 4 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ONCOLYTIC HSV-VECTOR | 2014 |
|
RU2719190C2 |
| RECOMBINANT ONCOLYTIC VIRUS, METHOD FOR ITS PRODUCTION, ITS APPLICATION AND THE DRUG ON ITS BASIS | 2020 |
|
RU2795230C1 |
| CONDITIONALLY REPLICATING ADENOVIRUS | 2012 |
|
RU2642293C2 |
| FLAVIVIRUS WITH BIPARTITE GENOME AND USING IT | 2008 |
|
RU2527891C2 |
| HERPETIC FEVER VIRUS VACCINES | 2010 |
|
RU2575067C2 |
| VIRAL PARTICLES CONTAINING ALPHAVIRUS VECTOR AND METHOD FOR PREPARING SAID VIRAL PARTICLE | 2004 |
|
RU2398875C2 |
| GENE THERAPY OF OPHTHALMIC DISORDERS | 2016 |
|
RU2762747C2 |
| ONCOLYTIC VIRAL VECTORS AND THEIR APPLICATION | 2018 |
|
RU2771110C2 |
| DOUBLE VECTOR FOR SUPPRESSION OF HUMAN IMMUNODEFICIENCY VIRUS | 2010 |
|
RU2562868C2 |
| POLYVALENT VIRAL VECTORS AND SYSTEM FOR PRODUCING THEREOF | 2005 |
|
RU2416646C2 |
